REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Price, Forecast & Analysis

NASDAQ:RDHL • US7574683014

0.96 USD
-0.02 (-2.34%)
Last: Feb 23, 2026, 05:59 PM

RDHL Key Statistics, Chart & Performance

Key Statistics
Market Cap4.91M
Revenue(TTM)8.04M
Net Income(TTM)-8.27M
Shares5.11M
Float12.78K
52 Week High3.6
52 Week Low0.91
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.47
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2011-02-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
RDHL short term performance overview.The bars show the price performance of RDHL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

RDHL long term performance overview.The bars show the price performance of RDHL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RDHL is 0.96 USD. In the past month the price decreased by -29.41%. In the past year, price decreased by -71.17%.

REDHILL BIOPHARMA LTD-SP ADR / RDHL Daily stock chart

RDHL Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
RDHL Full Technical Analysis Report

RDHL Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to RDHL. Both the profitability and financial health of RDHL have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RDHL Full Fundamental Analysis Report

RDHL Financial Highlights

Over the last trailing twelve months RDHL reported a non-GAAP Earnings per Share(EPS) of -2.47. The EPS decreased by -100.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%33.33%
Sales Q2Q%58.59%
EPS 1Y (TTM)-100.3%
Revenue 1Y (TTM)23.17%
RDHL financials

RDHL Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next Year82.69%
RDHL Analyst EstimatesRDHL Analyst Ratings

RDHL Ownership

Ownership
Inst Owners0.51%
Ins OwnersN/A
Short Float %490.65%
Short Ratio0.11
RDHL Ownership

RDHL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO31.54954.38B
JNJ JOHNSON & JOHNSON21.1584.231B
MRK MERCK & CO. INC.22.88303.452B
PFE PFIZER INC9.01151.524B
BMY BRISTOL-MYERS SQUIBB CO10.07123.489B
ZTS ZOETIS INC18.3256.752B
RPRX ROYALTY PHARMA PLC- CL A8.7726.045B
VTRS VIATRIS INC6.3118.336B
ELAN ELANCO ANIMAL HEALTH INC23.6712.412B
AXSM AXSOME THERAPEUTICS INC213.399.261B

About RDHL

Company Profile

RDHL logo image RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Company Info

REDHILL BIOPHARMA LTD-SP ADR

21 Ha'arba'a St.

TEL AVIV-YAFO 64739 IL

CEO: Dror Ben-Asher

Employees: 35

RDHL Company Website

RDHL Investor Relations

Phone: 97235413131

REDHILL BIOPHARMA LTD-SP ADR / RDHL FAQ

What does RDHL do?

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.


What is the stock price of REDHILL BIOPHARMA LTD-SP ADR today?

The current stock price of RDHL is 0.96 USD. The price decreased by -2.34% in the last trading session.


Does REDHILL BIOPHARMA LTD-SP ADR pay dividends?

RDHL does not pay a dividend.


What is the ChartMill technical and fundamental rating of RDHL stock?

RDHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the Short Interest ratio of REDHILL BIOPHARMA LTD-SP ADR (RDHL) stock?

The outstanding short interest for REDHILL BIOPHARMA LTD-SP ADR (RDHL) is 490.65% of its float.